{"id":1011878,"date":"2026-10-20T12:41:45","date_gmt":"2026-10-20T16:41:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/suewallst-reminds-shareholders-of-a-lead-plaintiff-deadline-of-december-7-2026-in-the-chemours-company-lawsuit-cc\/"},"modified":"2026-10-20T12:41:45","modified_gmt":"2026-10-20T16:41:45","slug":"suewallst-reminds-shareholders-of-a-lead-plaintiff-deadline-of-december-7-2026-in-the-chemours-company-lawsuit-cc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/suewallst-reminds-shareholders-of-a-lead-plaintiff-deadline-of-december-7-2026-in-the-chemours-company-lawsuit-cc\/","title":{"rendered":"SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of December 7, 2026 in The Chemours Company Lawsuit – CC"},"content":{"rendered":"

\nTime-Sensitive: Allegations Focus on 2026 EBITDA Guidance Representations. The lawsuit asserts that Chemours reaffirmed a full-year outlook that allegedly ignored aftermarket prebuy activity, which pulled Opteon refrigerant sales from 2026 back into 2025.
\n<\/h2>\n
\n

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) — SueWallSt alerts investors in The Chemours Company (NYSE: CC) of a pending securities class action concerning the specialty chemicals company’s 2026 EBITDA guidance. Class Period: February 20, 2026 through August 4, 2026.\u00a0Check if you might be eligible to recover your investment losses<\/u><\/a> or contact Joseph E. Levi, Esq. at jlevi@SueWallSt.com<\/u><\/a> or (888) SueWallSt.<\/p>\n

Chemours cut its full-year adjusted EBITDA guidance from $800 million-$900 million to $775 million-$825 million, a $50 million reduction at the midpoint. CC shares dropped 18.63% on the news. The deadline to apply for lead plaintiff appointment is December 7, 2026.<\/p>\n

\n “Investors deserve transparency about material risks that could affect their investments, including whether a full-year forecast already reflected sales booked in the prior year. The complaint raises serious questions about whether Chemours’ reaffirmed $800 million to $900 million range accounted for the 2025 aftermarket channel fill the Company later described,”<\/em> said Joseph E. Levi, Esq.<\/p>\n

\n The Alleged North American Aftermarket Prebuy Concentration<\/strong>\n <\/p>\n

Management introduced the full-year range on February 19, 2026. During that call, an analyst asked how quarterly earnings would climb from a first-quarter midpoint near $135 million to roughly $200 million by midyear. Management replied, “We have full confidence in our full year guide,” and said it expected “earnings growth in all 3 of our businesses.”<\/p>\n

The lawsuit asserts that this confidence lacked a reasonable basis because North American distributors and technicians had already stocked up on Opteon blends during 2025. The outlook was reaffirmed on May 5, 2026, with management pointing to higher demand in the Thermal & Specialized Solutions (TSS) refrigerant segment. As alleged, the guidance was set too aggressively from the start because it treated pulled-forward sales as recurring demand.<\/p>\n

\n AIM Act Channel Fill and Chemours’ 2026 EBITDA Guidance<\/strong>\n <\/p>\n